Investigating the early factors that drive changes in prostate cancer behavior
Targeting Early Drivers of Prostate Cancer Lineage Plasticity
This study is looking at how prostate cancer can change and become harder to treat, especially when it stops responding to usual therapies, and it aims to find ways to stop these changes so that patients with advanced prostate cancer can have better treatment options.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11130536 on NIH RePORTER |
What this research studies
This research focuses on understanding how prostate cancer can change its characteristics, particularly when it becomes resistant to standard treatments. By analyzing patient biopsies, the study aims to identify key genetic factors that contribute to this change, known as lineage plasticity. The goal is to develop strategies to prevent these changes from occurring, which could lead to more effective treatments for patients with advanced prostate cancer. The research employs advanced genomic analysis techniques to uncover these critical factors.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with advanced prostate cancer, particularly those whose tumors have shown resistance to androgen-based therapies.
Not a fit: Patients with early-stage prostate cancer or those whose tumors are not resistant to androgen therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that prevent the progression of prostate cancer to more aggressive forms.
How similar studies have performed: Previous research has shown promise in targeting genetic factors in cancer treatment, suggesting that this approach could yield significant advancements.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Alumkal, Joshi James — University of Michigan at Ann Arbor
- Study coordinator: Alumkal, Joshi James
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.